|The cost of domestic violence to the Australian economy: Part 1|
Commonwealth of Australia 90, 2004
|Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review|
B Parkinson, C Sermet, F Clement, S Crausaz, B Godman, S Garner, ...
Pharmacoeconomics 33 (9), 905-924, 2015
|Cost‐effectiveness of lumbar artificial intervertebral disc replacement: driven by the choice of comparator|
B Parkinson, S Goodall, P Thavaneswaran
ANZ Journal of Surgery 83 (9), 669-675, 2013
|Financial cost of lymphedema borne by women with breast cancer|
J Boyages, Y Xu, S Kalfa, L Koelmeyer, B Parkinson, H Mackie, H Viveros, ...
Psycho‐oncology 26 (6), 849-855, 2017
|Integrating health economics into the product development cycle: a case study of absorbable pins for treating hallux valgus|
L Vallejo-Torres, L Steuten, B Parkinson, AJ Girling, MJ Buxton
Medical Decision Making 31 (4), 596-610, 2011
|Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents|
JM Langton, P Srasuebkul, R Reeve, B Parkinson, Y Gu, NA Buckley, ...
Implementation Science 10 (1), 25, 2015
|Cost of Cancer in NSW|
Sydney: Cancer Council of NSW, 2007
|Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: a systematic review and critique|
B Parkinson, SA Pearson, R Viney
The European Journal of Health Economics 15 (1), 93-112, 2014
|The cost-effectiveness of mandatory folic acid fortification in Australia|
V Rabovskaja, B Parkinson, S Goodall
The Journal of nutrition 143 (1), 59-66, 2013
|Living with Parkinson’s disease: challenges and positive steps for the future|
Report for Parkinson’s Australia (Access Economics), 2007
|Investigating consumer medicine information (I-CMI) project|
P Aslani, K Hamrosi, E Feletto, DK Raynor, P Knapp, B Parkinson
Sydney: The Pharmacy Guild of Australia, Australian Government Department of …, 2010
|Considering consumer choice in the economic evaluation of mandatory health programmes: A review|
B Parkinson, S Goodall
Health policy 101 (3), 236-244, 2011
|Real-world evidence: a comparison of The Australian Herceptin Program and clinical trials of trastuzumab for HER2-positive metastatic breast cancer|
B Parkinson, R Viney, M Haas, S Goodall, P Srasuebkul, SA Pearson
Pharmacoeconomics 34 (10), 1039-1050, 2016
|Cost‐effectiveness of the BRECONDA decision aid for women with breast cancer: Results from a randomized controlled trial|
B Parkinson, KA Sherman, P Brown, LKE Shaw, J Boyages, LD Cameron, ...
Psycho‐oncology 27 (6), 1589-1596, 2018
|Long‐term health care costs for patients with prostate cancer: a population‐wide longitudinal study in New South Wales, Australia|
P Cronin, B Kirkbride, A Bang, B Parkinson, D Smith, P Haywood
Asia‐Pacific Journal of Clinical Oncology 13 (3), 160-171, 2017
|Investigating consumer medicine information (CMI) report. CMI effectiveness tender|
P Aslani, K Hamrosi, E Feletto, P Knapp, B Parkinson, J Hughes, L Nissen, ...
The Pharmacy Guild of Australia and Department of Health and Ageing, 2010
|Comparing theory and non-theory based implementation approaches to improving referral practices in cancer genetics: a cluster randomised trial protocol|
A Morrow, E Hogden, YJ Kang, J Steinberg, K Canfell, MJ Solomon, ...
Trials 20 (1), 1-12, 2019
|The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience|
TV Ariyaratne, Z Ademi, M Huq, F Rosenfeldt, SJ Duffy, B Parkinson, ...
Applied health economics and health policy 16 (5), 661-674, 2018
|Comment on:" Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review"/Authors' Reply to Palozzo and Messori:" Disinvestment and Value …|
AC Palozzo, A Messori, B Parkinson, AG Elshaug
Pharmacoeconomics 34 (4), 419, 2016
|Discounting in economic evaluations in health care: A brief review|
B Parkinson, RDA Lourenço